Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates [Yahoo! Finance]
Summit Therapeutics Inc. (SMMT)
Last summit therapeutics inc. earnings: 6/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
summitplc.com/investors/investor-centre
Company Research
Source: Yahoo! Finance
Summit Therapeutics climbed by 15.44 percent on Wednesday to close at $17.94 apiece, as investors repositioned portfolios ahead of updates on a clinical trial for its lung cancer treatment candidate, Ivonescimab. Within the second quarter of the year, Summit Therapeutics Inc. (NASDAQ:SMMT) is targeting to conduct an early analysis of its Harmoni 3 trial for the squamous group to see the efficacy of Ivonescimab combined with chemotherapy in patients with first-line metastatic non-small cell lung cancer (NSCLC). Final data on the progression-free survival (PFS) is targeted in the second half of the year. Photo by Roger Brown on Pexels Meanwhile, enrollment is underway for the non-squamous group, and is targeted for completion in the second half of the year. Final PFS is expected in the first half of 2027. Meanwhile, Summit Therapeutics Inc. (NASDAQ:SMMT) said that Ivonescimab is likewise being studied in a phase 3 trial to evaluate its efficacy in combination with ligufalimab—a
Show less
Read more
Impact Snapshot
Event Time:
SMMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SMMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting Summit Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
SMMT
News
- Summit Therapeutics (SMMT) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now [Yahoo! Finance]Yahoo! Finance
- Summit Therapeutics (SMMT) was downgraded by Jefferies Financial Group Inc. from "buy" to "hold". They now have a $15.00 price target on the stock.MarketBeat
- Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
- Summit Therapeutics (SMMT) was upgraded by Zacks Research from "strong sell" to "hold".MarketBeat
SMMT
Earnings
- 2/23/26 - Beat
SMMT
Sec Filings
- 2/23/26 - Form S-8
- 2/23/26 - Form 10-K
- 2/23/26 - Form 8-K
- SMMT's page on the SEC website